Radiation/Temozolomide and Immunotherapy With Daratumumab to Improve Antitumor Efficacy in Glioblastoma

NCT04922723 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

16

Enrollment

OTHER

Sponsor class

Conditions

Glioblastoma

Interventions

DRUG: Daratumumab

Sponsor

West Virginia University